WASHINGTON | October 23, 2026 | An experimental personalized messenger RNA (mRNA) cancer vaccine has shown sustained benefits in reducing the risk of melanoma returning after surgery, with a large Phase 3 trial reporting positive results, marking a significant development in efforts to use individualized treatments against cancer.
The vaccine, called intismeran autogene, formerly known as V940 or mRNA-4157, is being developed by Moderna in partnership with Merck. It is designed to work alongside pembrolizumab, an immunotherapy drug marketed as Keytruda, to help the immune system recognize and attack cancer cells.
In an August 19, 2026, announcement, Merck and Moderna said their Phase 3 INTerpath-001 trial met its primary endpoints of recurrence-free survival and distant metastasis-free survival in patients with high-risk melanoma that had been completely removed through surgery. The companies said they planned to present detailed findings at a future medical meeting and engage with regulators regarding potential applications for approval.
Earlier evidence came from the randomized Phase 2b KEYNOTE-942 trial involving 157 patients with high-risk stage III or IV melanoma following complete surgical removal. In a five-year follow-up reported in 2026, the combination of the vaccine and pembrolizumab was associated with a 49% reduction in the relative risk of cancer recurrence or death compared with pembrolizumab alone. The combination also reduced the relative risk of distant metastasis or death by 59%, according to the published study results. These figures represent relative risk reductions, not the percentage of patients guaranteed to avoid recurrence.
The vaccine is tailored to each patient’s tumor. After analyzing tumor tissue to identify mutations that may produce recognizable targets, researchers design an mRNA treatment intended to instruct the body to produce these targets and stimulate an immune response against cancer cells carrying them. Pembrolizumab works differently by blocking the PD-1 immune checkpoint, helping immune cells maintain their ability to attack cancer.
The approach builds on advances in cancer immunotherapy, which has transformed treatment for some patients with advanced melanoma. The US National Cancer Institute identifies surgery, checkpoint inhibitors and targeted therapies among established treatment options, while personalized cancer vaccines remain under clinical evaluation. The US Food and Drug Administration approved pembrolizumab for certain patients with melanoma following surgery in 2019, with its approved uses subsequently expanding. The vaccine combination is a separate investigational treatment.
Despite the encouraging results, the personalized vaccine is not yet an established, widely available treatment. The Phase 3 findings are a major step toward determining whether the combination can become a new option for patients at high risk of melanoma recurrence, but regulatory review and further detailed assessment of the evidence remain important.
The ongoing research also reflects a broader shift toward precision medicine, in which treatments are designed around the molecular characteristics of an individual patient’s cancer rather than relying solely on therapies intended for broad groups of patients.
Paraluman P. Funtanilla
Paraluman P. Funtanilla is Tutubi News Magazine's Marketing Specialist and is a Contributing Editor. She finished her degree in Communication Arts in De La Salle Lipa. She has worked as a Digital Marketer for start-up businesses and small business spaces for the past two years. She has earned certificates from Coursera on Brand Management: Aligning Business Brand and Behavior and Viral Marketing and How to Craft Contagious Content. She also worked with Asia Express Romania TV Show.
- Paraluman P. Funtanilla
- Paraluman P. Funtanilla
- Paraluman P. Funtanilla
- Paraluman P. Funtanilla
